What is HC Wainwright's Forecast for PLYX Q2 Earnings?

Key Points

• HC Wainwright expects Polaryx Therapeutics (NASDAQ: PLYX) to report Q2 2026 EPS of ($0.05) and reiterated a Buy rating with a $7.00 price target.
• The firm’s longer-term estimates point to continued losses, including FY2026 EPS of ($0.22) and FY2027 EPS of ($0.28), with quarterly projections staying around a $0.06 to $0.07 loss per share.
• PLYX last reported EPS of ($0.03) for the prior quarter, and the stock recently traded near $2.33, well below the analyst price target and far under its 12-month high of $48.91.

Polaryx Therapeutics, Inc. (NASDAQ:PLYX - Free Report) - Equities researchers at HC Wainwright issued their Q2 2026 EPS estimates for Polaryx Therapeutics in a note issued to investors on Thursday, July 9th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.05) for the quarter. HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. HC Wainwright also issued estimates for Polaryx Therapeutics' Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.22) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.28) EPS.

Polaryx Therapeutics (NASDAQ:PLYX - Get Free Report) last released its earnings results on Monday, March 23rd. The company reported ($0.03) EPS for the quarter.

A number of other brokerages have also recently commented on PLYX. Wall Street Zen cut Polaryx Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday. Weiss Ratings upgraded Polaryx Therapeutics from a "sell (e-)" rating to a "sell (e)" rating in a research report on Wednesday, July 1st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Polaryx Therapeutics presently has a consensus rating of "Hold" and an average price target of $8.50.

Polaryx Therapeutics Stock Performance

PLYX stock opened at $2.33 on Monday. Polaryx Therapeutics has a 12-month low of $2.01 and a 12-month high of $48.91. The firm has a market cap of $109.58 million and a PE ratio of -46.60. The business has a 50-day moving average price of $2.86.

Insider Activity

In related news, CEO Alex Keun Mo Yang purchased 88,453 shares of the company's stock in a transaction dated Wednesday, May 27th. The stock was acquired at an average cost of $4.07 per share, for a total transaction of $360,003.71. Following the completion of the transaction, the chief executive officer directly owned 24,233,249 shares of the company's stock, valued at approximately $98,629,323.43. This trade represents a 0.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Key Polaryx Therapeutics News

Here are the key news stories impacting Polaryx Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Polaryx Therapeutics and kept its $7.00 price objective, signaling continued analyst confidence in the company’s outlook.
• Neutral Sentiment: The firm released earnings estimates for Q2 2026 through FY2027, projecting ongoing losses, including FY2026 EPS of ($0.22) and FY2027 EPS of ($0.28). The forecast reflects expected development-stage losses rather than a near-term profitability surprise.
• Neutral Sentiment: Quarterly estimates were also updated for Q2 2026 ($0.05), Q3 2026 ($0.06), Q4 2026 ($0.06), and multiple 2027 quarters at ($0.07) per share, but there was no new clinical or regulatory catalyst in the report. Polaryx Therapeutics stock page

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.